NEWPORT BEACH, Calif. — May 15th, 2026 – Lionheart Health, Inc., a leader in bioelectric stimulation controlled protein expression and regenerative health technologies, today announced the development of AortaCell AI™, a next-generation artificial intelligence platform designed to help physicians identify which aortic aneurysms are likely to grow, destabilize, or require earlier intervention.
AortaCell AI™ combines advanced MRI vascular imaging, biomechanical analysis, artificial intelligence, and longitudinal patient monitoring into a single integrated platform intended to support more personalized aneurysm management decisions.
Current aneurysm monitoring methods rely heavily on vessel diameter measurements, despite the fact that many aneurysms rupture below surgical thresholds while others remain stable for years. Lionheart Health believes a more intelligent and predictive approach is needed.
“AortaCell AI™ is being developed to move aneurysm medicine from reactive to predictive,” said Howard J. Leonhardt, Executive Chairman and Co-CEO of Lionheart Health. “Our goal is to help physicians identify dangerous aneurysm behavior earlier and eventually support regenerative intervention strategies before catastrophic progression occurs.”
The AortaCell AI™ platform is being designed to analyze:
- Wall stress distribution
- Blood flow dynamics
- Tissue elasticity
- Inflammatory signatures
- Thrombus burden
- Longitudinal aneurysm remodeling trends
- Patient-specific vascular risk profiles
The platform aims to generate a personalized “Aneurysm Stability Index™” designed to help clinicians better understand:
- Which aneurysms may remain stable
- Which aneurysms are likely to grow rapidly
- Which patients may require earlier intervention
- Which patients may respond to regenerative vascular therapies
Lionheart Health also plans to integrate regenerative treatment monitoring into the AortaCell AI™ ecosystem, including evaluation of bioelectric stimulation therapies such as BodStim™ and future AortaCell™ regenerative vascular programs focused on vascular repair, endothelial support, inflammation reduction, and tissue stabilization.
Future planned capabilities under development include:
- AI-powered aneurysm growth forecasting
- Rupture risk prediction
- MRI-based vascular digital twin modeling
- Longitudinal vascular health tracking
- Personalized regenerative treatment recommendations
- Remote patient monitoring dashboards
The company believes the same AI vascular intelligence platform may later expand into additional cardiovascular applications including:
- Carotid artery disease
- Peripheral vascular disease
- Coronary plaque instability
- Heart failure remodeling
- Vascular aging analytics
The AortaCell AI™ initiative represents part of Lionheart Health’s broader strategy to combine artificial intelligence, regenerative medicine, bioelectric stimulation, and advanced biomarker analysis into personalized health optimization platforms.
Lionheart Health is known for its development programs in bioelectric stimulation controlled protein expression, regenerative health technologies, healthspan optimization, and AI-guided wellness and longevity programs.
For more information visit:
www.LionheartHealth.com